Title: Global pricing strategies for innovative essential drugs
Authors: Jerome Dumoulin
Addresses: Institut de Recherche Economique sur la Production et le Developpement, Universite Pierre Mendes-France, BP 47, F-38040 Grenoble Cedex, France
Abstract: This paper examines the pricing of essential innovative medicines according to alternative strategies of firms i) either a country-wise price of discrimination according to the revenues of the consumers of these countries; ii) or a single worldwide price. Two counter-strategies by countries| governments are related to these strategies parallel imports and compulsory licensing of patents. For each strategy, firms| profit and affordability of such drugs are calculated with a simulation model. We show that price discrimination maximises both indicators. Despite this result, some firms prefer to set a unique worldwide price, maybe because they are afraid that low priced medicines would find their way onto the black market and end up in the potentially higher price countries.
Keywords: pharmaceuticals; discrimination prices; parallel imports; compulsory licensing.
International Journal of Biotechnology, 2001 Vol.3 No.3/4, pp.338-349
Published online: 13 Jul 2003 *
Full-text access for editors Full-text access for subscribers Purchase this article Comment on this article